Alphalyse and Bavarian Nordic A/S significantly shorten the time necessary to document HCP impurities in COVID-19 vaccine candidate for Phase 3 clinical trial – through world’s first MS-based HCP analysis under GMP conditions
ODENSE, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Alphalyse has performed the world’s first GMP-certified mass spectrometry (MS)-based Host Cell Protein (HCP) analysis for product release testing for Phase 3 clinical trial, after being certified by the Danish Health and Medicines Authority to perform quality control of biological API using MS-based HCP analysis under GMP.
On September 2, 2022, Bavarian Nordic A/S announced the start of Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. ABNCoV2 is being developed as a universal booster to any other type of COVID-19 vaccine and has shown potential to boost neutralizing antibodies against SARS-CoV-2, including variants of concern, to levels associated with a high degree of protection. The goal is to create a longer-lasting vaccine protection with broader efficacy that obviates the need for continuously adapting to new variants of the SARS-CoV-2 virus. The development of ABNCoV2 is being funded through an agreement with the Danish State, and the Danish Ministry of Health has committed DKK 800M to support the ongoing Phase 3 clinical trial. Prior to the Phase 3 clinical trial, Bavarian Nordic contracted Alphalyse to perform product release testing under GMP conditions, thereby becoming the first pharmaceutical company in the world to use MS-based HCP analysis for Phase 3 clinical trial documentation.
One of the biggest challenges in developing vaccines is ensuring and documenting that the downstream process consistently produces a safe product with low HCPs levels. Alphalyse offers a unique LC-MS-based HCP analysis, used for more than 300 biotherapeutic projects, which is significantly faster than traditional methods for product impurity documentation and enables pharmaceutical companies to identify and eliminate specific process-related impurities, thereby further increasing the quality, safety, and efficacy of their product. This makes the Alphalyse method particularly useful for developing vaccines during a global pandemic when the time to create a process-specific ELISA is limited.
The unique Alphalyse method has the potential to significantly reduce the time required to document new vaccines, from the current industry standard of 12-18 months to as little as 4 months, while being as safe or safer than other methods.
Thomas Kofoed, co-founder and Chief Executive Officer of Alphalyse, says: “This is a major milestone, not only for Alphalyse, but for the many companies struggling with the limitations of ELISA. With the potential for using mass spectrometry as a release assay, we can assist developers with short time frames, such as those producing vaccines during a pandemic, and very complex products, such as cell and gene therapies, in getting their HCP release assay in place for Phase 3 clinical trial and for marketed products.”
Alphalyse is a specialist contract research organization that supports biopharmaceutical companies in developing and manufacturing patient-safe products, such as mAbs, vaccines, recombinant proteins, and cell and gene therapies. Alphalyse has offices in Denmark and the USA, supporting clients with the analysis of protein-related impurities and protein characterization, and has completed more than 10,000 customer projects since 2002.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing, and commercialization of life-saving vaccines. Using their live virus vaccine platform technology, MVA-BN®, they have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including the development of a next generation COVID-19 vaccine.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
For more information, please contact
Thomas Kofoed, CEO, Alphalyse
Phone: +45 6310 6501
US office: (650) 543-3193
Distributed on January 3, 2023.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Coloplast Finance B.V. - Decisions at the Annual General Meeting31.1.2023 20:24:07 CET | Press release
Decisions at the Annual General Meeting On 31 January 2023, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S approved the annual report for the financial year 2021/22 (for the first 7-months from incorporation until 30 September 2022). Attachment 01_2023_Annual General Meeting_Coloplast Finance
Nokia Corporation: Repurchase of own shares on 31.01.202331.1.2023 20:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 31 January 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 31.01.2023 Espoo, Finland – On 31 January 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL261,4854.33CEUX19,9384.34AQEU23,7644.33TQEX12,8134.34Total318,0004.33 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 20
GA-ASI's Eaglet Takes Its First Flight31.1.2023 19:00:00 CET | Press release
SAN DIEGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- General Atomics Aeronautical Systems, Inc. (GA-ASI) flew a new survivable Air-Launched Effect (ALE) for the first time as part of a flight demonstration based out of the Dugway Proving Grounds, Utah, on Dec. 8, 2022. The ALE, known as Eaglet, was launched from a U.S. Army MQ-1C Gray Eagle Extended Range (GE-ER) Unmanned Aircraft System (UAS). The Eaglet flight was jointly funded by GA-ASI and the U.S. Army Combat Capabilities Development (DEVCOM) Army Research Laboratory (ARL) and Aviation & Missile Center (AvMC). "The first flight of the Eaglet was an important milestone for the GA-ASI/U.S. Army team," said GA-ASI President David R. Alexander. "Eaglet is intended to be a low-cost, survivable UAS with the versatility to be launched from a Gray Eagle, rotary-wing aircraft, or ground vehicles. It enables extended reach of sensors and increased lethality while providing survivability for manned aircraft." Eaglet fits into the 'ALE Large' catego
Changes to Vallourec’s management team31.1.2023 18:41:38 CET | Press release
Changes to Vallourec’s management team Meudon, France, 31January 2023 – As part of its "New Vallourec" plan, led by Philippe Guillemot, Chairman and Chief Executive Officer, the Group has developed a three-region organization (North America, South America, and Eastern Hemisphere) to simplify and optimize the operations. This new organization aims at making the Group more efficient and more agile, closer to its customers, and to enhance its industrial performance, through two export bases, Brazil, and Asia. This new organization has led to changes in its Executive Committee, effective February 1, 2023: - Laurent Dubedout is appointed Senior Vice-President, Business Line OCTG, Services and Accessories, Group & Eastern Hemisphere and joins the Executive Committee. - Jacky Massaglia is appointed Senior Vice-President Business Line Project Line Pipe and Process and joins the Executive Committee. - Philippe Carlier, who was SVP Technology and Industry, becomes SVP Group Industry and Eastern
Information on the total number of voting rights and shares31.1.2023 18:00:00 CET | Press release
Ghent, Belgium, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Press release - regulated information Biotalys NV (hereafter the “Company” or “Biotalys”), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions (Euronext - BTLS), today announces that 10,000 new shares were issued on 18 January 2023 as a result of the exercise of subscription rights under the Company’s long term incentive plan. In view hereof, and in accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings (the “Belgian Act”), the outstanding share capital and outstanding voting securities of the Company can be summarised as follows: Share capital: EUR 44,564,320.02Total number of securities carrying voting rights: 30,959,454 (all ordinary shares)Total number of voting rights (= denominator): 30,959,454 (all relating to ordinary shares)Number of rights to subscribe for securities carrying voting rights not yet issued: 2,162,109 “ESOP War